Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

1. Chan, A.
2. Delaloge, S.
3. Holmes, F.A.
4. Moy, B.
5. Iwata, H.
6. Harvey, V.J.
7. Robert, N.J.
8. Silovski, T.
9. Gokmen, E.
10. von Minckwitz, G.
11. Ejlertsen, B.
12. Chia, S.K.L.
13. Mansi, J.
14. Barrios, C.H.
15. Gnant, M.
16. Buyse, M.
17. Gore, I.
18. Smith, J.
19. Harker, G.
20. Masuda, N.
21. Petrakova, K.
22. Zotano, A.G.
23. Iannotti, N.
24. Rodriguez, G.
25. Tassone, P.
26. Wong, A.
27. Bryce, R.
28. Ye, Y.
29. Yao, B.
30. Martin, M.
31. Erakutsi egile guztiak +